Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2879251 | 1.00 | ALDH1A1 (0.32) | ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL12943644 | 0.83 | HSP90AA1 (0.33) | ALDH1A1 | |
| SCHEMBL714279 | 0.83 | CHRM2 (0.31) | — | |
| SCHEMBL9597464 | 0.83 | CHRM2 (0.31) | — | |
| SCHEMBL8942860 | 0.82 | — | — | |
| SCHEMBL8942857 | 0.82 | — | — | |
| SCHEMBL13283453 | 0.81 | CHRM2 (0.33) | — | |
| SCHEMBL10737649 | 0.80 | — | — | |
| SCHEMBL14429331 | 0.79 | — | — | |
| SCHEMBL13393993 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103319450-A | Preparation method of optical active (S)-2-(2,2-substitute-1,3-dioxolane-4-yl) ethanol | UNIV FUDAN | 2013-09-25 | — | — | CN | disclosed |
| US-8415347-B2 | Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| US-8415347-B2 | Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| US-20100331325-A1 | NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES | CID-NUNEZ JOSE MARIA | 2010-12-30 | — | — | US | disclosed |
| US-7799785-B2 | Substituted tetracyclic tetahydrofuran, pyrrolidine and tetrahydrothiophene derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-21 | — | — | US | disclosed |
| US-20090023721-A1 | Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament | MEGENS ANTONIUS ADRIANUS HENDR | 2009-01-22 | — | — | US | disclosed |
| US-20080287450-A1 | Novel Substituted Tetracyclic Tetahydrofuran, Pyrrolidine And Tetrahydrothiophene Derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2008-11-20 | — | — | US | disclosed |
| EP-1891073-A1 | NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES AND THEIR USE AS A MEDICAMENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1824820-A2 | SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN,PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006125812-A1 | NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES AND THEIR USE AS A MEDICAMENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006061392-A2 | SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |
| US-20050048108-A1 | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells | G.O.T. THERAPEUTICS GMBH (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1345893-A2 | SULPHUR-CONTAINING AMPHIPHILIC AGENTS FOR THE TRANSFER OF BIOLOGICALLY ACTIVE MOLECULES INTO CELLS | G.O.T. Therapeutics GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051800-A2 | SULPHUR-CONTAINING AMPHIPHILIC AGENTS FOR THE TRANSFER OF BIOLOGICALLY ACTIVE MOLECULES INTO CELLS | G.O.T. THERAPEUTICS GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-0467721-B1 | Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same | MITSUBISHI RAYON CO (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5480580-A | COMPOUNDS FOR VISUAL AIDS WITH GOOD STABILITY | MITSUBISHI RAYON COMPANY LTD. (JP) | 1996-01-02 | — | — | US | disclosed |
| EP-0467721-A1 | Optically active compound having a delta- valerolactone ring and liquid crystal composition containing same | MITSUBISHI RAYON CO., LTD (JP) | 1992-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331325-A1 | NOVEL SUBSTITUTED TETRACYCLIC TETRAHYDROFURAN, PYRROLIDINE AND TETRAHYDROTHIOPHENE DERIVATIVES | HTR2C, TPH2, HTR2A | ALDH1A1 556/4885MAPT 1309/4885KDM4E 4527/4885 |
| US-20090023721-A1 | Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament | HTR2C, HTR5A, TPH2 | ALDH1A1 496/4885MAPT 1775/4885KDM4E 4378/4885 |
| US-20080287450-A1 | Novel Substituted Tetracyclic Tetahydrofuran, Pyrrolidine And Tetrahydrothiophene Derivatives | TPH2, HTR2C, TPH1 | ALDH1A1 454/4885MAPT 1690/4885KDM4E 3796/4885 |
| US-20050048108-A1 | Sulphur-containing amphiphilic agents for the transfer of biologically active molecules into cells | PHOSPHO1, SNRPE, SELENOI | ALDH1A1 2138/4885MAPT 4102/4885KDM4E 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.